title: Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant.
abstract: Hepatosplenic T-cell lymphoma (HTCL) is a rare malignancy. Prognosis is poor with only a few case reports of long-term survivors. While HTCL universally involves the bone marrow, the condition has been most often treated with multimodal lymphoma specific chemotherapy. We report a durable, sustained first remission in an adolescent treated for HTCL who received induction therapy according to a high risk T-cell leukemia regimen, a nucleoside analog-based consolidation, and allogeneic transplantation associated with GVHD.
authors.affiliation: Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA. eschafe1@jhmi.edu
authors.forename: Eric
authors.initials: E
authors.lastname: Schafer
authors.forename: Allen
authors.initials: A
authors.lastname: Chen
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Arceci
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015458:Leukemia, T-Cell / Q000188:drug therapy; D008113:Liver Neoplasms / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000473:pathology / Q000628:therapy*; D009705:Nucleosides / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D013160:Splenic Neoplasms / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009705:Nucleosides